OPRX Quote, Financials, Valuation and Earnings

Amedisys has a net margin of -42.82% compared to OptimizeRx's net margin of 2.88%. OptimizeRx's return on equity of -20.12% beat Amedisys's return on equity of 7.23%.

OptimizeRx has a consensus price target of $9.79, signalling upside risk potential of 92.25%. On the other hand Amedisys has an analysts' consensus of $96.33 which suggests that it could grow by 7.09%. Given that OptimizeRx has higher upside potential than Amedisys, analysts believe OptimizeRx is more attractive than Amedisys.

OptimizeRx has a beta of 1.341, which suggesting that the stock is 34.097% more volatile than S&P 500. In comparison Amedisys has a beta of 0.726, suggesting its less volatile than the S&P 500 by 27.385%.

OptimizeRx has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Amedisys offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. OptimizeRx pays -- of its earnings as a dividend. Amedisys pays out -- of its earnings as a dividend.

OptimizeRx quarterly revenues are $21.3M, which are smaller than Amedisys quarterly revenues of $587.7M. OptimizeRx's net income of -$9.1M is lower than Amedisys's net income of $16.9M. Notably, OptimizeRx's price-to-earnings ratio is -- while Amedisys's PE ratio is 35.70x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for OptimizeRx is 1.05x versus 1.28x for Amedisys. Usually stocks with elevated PS ratios are considered overvalued.

Health Catalyst has a net margin of -42.82% compared to OptimizeRx's net margin of -19.29%. OptimizeRx's return on equity of -20.12% beat Health Catalyst's return on equity of -21.76%.

OptimizeRx has a consensus price target of $9.79, signalling upside risk potential of 92.25%. On the other hand Health Catalyst has an analysts' consensus of -- which suggests that it could grow by 61.15%. Given that OptimizeRx has higher upside potential than Health Catalyst, analysts believe OptimizeRx is more attractive than Health Catalyst.

OptimizeRx has a beta of 1.341, which suggesting that the stock is 34.097% more volatile than S&P 500. In comparison Health Catalyst has a beta of 1.315, suggesting its more volatile than the S&P 500 by 31.457%.

OptimizeRx has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Health Catalyst offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. OptimizeRx pays -- of its earnings as a dividend. Health Catalyst pays out -- of its earnings as a dividend.

OptimizeRx quarterly revenues are $21.3M, which are smaller than Health Catalyst quarterly revenues of $76.4M. OptimizeRx's net income of -$9.1M is higher than Health Catalyst's net income of -$14.7M. Notably, OptimizeRx's price-to-earnings ratio is -- while Health Catalyst's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for OptimizeRx is 1.05x versus 1.38x for Health Catalyst. Usually stocks with elevated PS ratios are considered overvalued.

Option Care Health has a net margin of -42.82% compared to OptimizeRx's net margin of 4.21%. OptimizeRx's return on equity of -20.12% beat Option Care Health's return on equity of 14.65%.

OptimizeRx has a consensus price target of $9.79, signalling upside risk potential of 92.25%. On the other hand Option Care Health has an analysts' consensus of -- which suggests that it could grow by 31.78%. Given that OptimizeRx has higher upside potential than Option Care Health, analysts believe OptimizeRx is more attractive than Option Care Health.

OptimizeRx has a beta of 1.341, which suggesting that the stock is 34.097% more volatile than S&P 500. In comparison Option Care Health has a beta of 1.332, suggesting its more volatile than the S&P 500 by 33.16%.

OptimizeRx has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Option Care Health offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. OptimizeRx pays -- of its earnings as a dividend. Option Care Health pays out -- of its earnings as a dividend.

OptimizeRx quarterly revenues are $21.3M, which are smaller than Option Care Health quarterly revenues of $1.3B. OptimizeRx's net income of -$9.1M is lower than Option Care Health's net income of $53.9M. Notably, OptimizeRx's price-to-earnings ratio is -- while Option Care Health's PE ratio is 19.20x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for OptimizeRx is 1.05x versus 0.84x for Option Care Health. Usually stocks with elevated PS ratios are considered overvalued.

Regional Health Properties has a net margin of -42.82% compared to OptimizeRx's net margin of -23.24%. OptimizeRx's return on equity of -20.12% beat Regional Health Properties's return on equity of -489.72%.

OptimizeRx has a consensus price target of $9.79, signalling upside risk potential of 92.25%. On the other hand Regional Health Properties has an analysts' consensus of -- which suggests that it could grow by 319.36%. Given that Regional Health Properties has higher upside potential than OptimizeRx, analysts believe Regional Health Properties is more attractive than OptimizeRx.

OptimizeRx has a beta of 1.341, which suggesting that the stock is 34.097% more volatile than S&P 500. In comparison Regional Health Properties has a beta of 0.916, suggesting its less volatile than the S&P 500 by 8.446%.

OptimizeRx has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Regional Health Properties offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. OptimizeRx pays -- of its earnings as a dividend. Regional Health Properties pays out -- of its earnings as a dividend.

OptimizeRx quarterly revenues are $21.3M, which are larger than Regional Health Properties quarterly revenues of $4.2M. OptimizeRx's net income of -$9.1M is lower than Regional Health Properties's net income of -$982K. Notably, OptimizeRx's price-to-earnings ratio is -- while Regional Health Properties's PE ratio is 0.13x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for OptimizeRx is 1.05x versus 0.17x for Regional Health Properties. Usually stocks with elevated PS ratios are considered overvalued.